CoChat

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Open access
Inagaki, Nobuya, Takeuchi, Masakazu, Oura, Tomonori, Imaoka, Takeshi, Seino, Yutaka · 2022 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of tirzepatide, a novel GIP and GLP-1 receptor agonist, compared with dulaglutide in Japanese patients with type 2 diabetes. Methods This multicentre, randomised, double-blind, parallel, active-controlled, phase 3 trial was conducted in 46 medical research centres and hospitals in Japan. Adults aged 20 years or older with type 2 diabetes who had discontinued oral antihyperglycaemic monotherapy or were treatment-naïve were included. Participants were randomly assigned (1:1:1:1) to receive tirzepatide (5, 10, or 15 mg) or dulaglutide (0·75 mg) once per week using a computer-generated random sequence with an Interactive Web Response System. Participants were stratified based on baseline HbA 1c (≤8·5% or >8·5%), baseline BMI ( 2 ), and washout of antidiabetic medication. Participants, investigators, and the sponsor were masked to treatment assignment. The starting dose of tirzepatide was 2·5 mg once per week for 4 weeks, which was then increased to 5 mg in the tirzepatide 5 mg treatment group. For the tirzepatide 10 and 15 mg treatment groups, increases by 2·5 mg occurred once every 4 weeks until the assigned dose was reached. The primary endpoint was mean change in HbA 1c from baseline at week 52 measured in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03861052. Finding…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00188-7

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 29 references

Cited by

See all 251

Metadata

Authors
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y.
Affiliations
  • Kyoto University (JP)
  • Eli Lilly (Japan) (JP)
  • Kansai Electric Power (Japan) (JP)
Corresponding author
Takeuchi, Masakazu
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-09
Volume
10
Issue
9
Pages
623-633
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4288740467
Cited by
226
References
29
Citations by year
2026: 42 · 2025: 63 · 2024: 58 · 2023: 49 · 2022: 14
FWCI
34.07
Type
journal article
Language
en
Update notices
erratum (2025-12-01)
Open access
Locations
  • The Lancet Diabetes & Endocrinology (acceptedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly Japan
  • Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, dulaglutide, type 2 diabetes, GIP/GLP-1 receptor agonist, monotherapy, HbA1c, treatment-naive patients, Japanese patients, drug safety, adverse events, dose comparison, weight gain, hypoglycemia
MeSH terms
Glucagon-Like Peptide-1 Receptor, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Japan, Male, Middle Aged, Recombinant Fusion Proteins, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00188-7
The paper
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00188-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.